Medical communications company, Prime Global, and healthcare technology company, Raremark®, announced that they have formed a strategic partnership to transform solutions for patients with rare diseases. Together, the companies will uncover insights into the entire patient journey that will allow the creation of truly patient-centric drug development and commercialisation programs. Focusing on the needs of patients is the key to powerful communications that make a tangible difference to patient outcomes.
Raremark is the first of its kind patient experience network in rare disease with its patient-powered knowledge platform, Xperiome, providing a robust foundation of patient insights to deliver innovative new therapies faster and smarter for the pharmaceutical industry. Building a community for people affected by rare conditions, sharing knowledge, and collecting real-world experience data, brings together patients and researchers to improve the lives of others. Prime Global, founded in 1997, is a medical communications and market access group leading the way in pharmaceutical and biotech marcomms.
Graeme Peterson, CEO of Prime Global, said: “Our strategic partnership enables laser focus in patient engagement for patients with rare diseases. By combining Raremark’s cutting-edge Xperiome platform for patients with our 23 years of award-winning medical communications experience, we can deliver patient-centric services and solutions that improve outcomes for both pharma and, most importantly, patients.”
Jeremy Edwards, Raremark’s CEO, said: “This exciting new collaboration with Prime Global provides a strategic foundation that will allow us to deliver significant value to our clients through our combined expertise. It will engage, empower and educate patients – ultimately gaining a deeper insight into their requirements to improve lives and accelerate the development and reach of new treatments.”
Peterson added, “Working closely with patients is vital and the bedrock of the services we develop for our clients. Raremark is at the forefront of innovation in patient engagement and our ability to collaborate brings new and exciting capabilities.
Prime Global has experienced exceptional organic growth in recent years, including the recent launch of Prime Access, a Market Access consultancy, and IRIS, a strategic consultancy. The company is proud to rank on several business growth lists such as the Sunday Times Fast Track 100 in 2018 and 2019, and of being selected as consultancy growth winners of the Alantra Fast Pharma 50 in 2019 and 2020.
About Prime Global
Prime Global is an international medical communications and market access group. Founded in 1997 by the CEO and Managing Director, Graeme Peterson PhD, it provides the world’s leading biotech, pharma and healthcare businesses with full-service professional communications covering healthcare strategy and consultancy, scientific and medical communications, consumer health, patient integrated science, and market access.
Prime Global comprises seven agencies (Prime, Spark, Onyx, Paragon, Scion, Core, and Cambridge), three consultancies (IRIS, Prime Access, and Only Oncology), as well as group-level teams for Creative, Digital, and more. Prime Global is rapidly growing, successful, and wholly independently owned. It employs over 230 people, with offices in the UK (London, Knutsford, Macclesfield, Brighton, Oxford, and Cambridge), the US (New York and San Francisco), and satellite locations in San Diego, Germany, and New Zealand.
Our highly qualified scientific teams deliver expertise across a wide range of therapy areas such as oncology, cardiovascular, diabetes and metabolic disorders, central nervous system and neurosciences, respiratory, infectious diseases, vaccines, HIV and virology, devices and diagnostics, sexual health and urology, nephrology, haematology, dermatology, gastrointestinal, rare and genetic disorders, and immuno-inflammation and allergy.
We believe passionately in the value of innovative and creative science communication to further our understanding of the world, and to benefit patients everywhere. Our philosophy is ‘people first’. People are at the heart of everything we do, from the colleagues we work with to the clients we support every day, and ultimately the patients helped by their products and services.
About Raremark
Raremark is a healthcare technology company with the first of its kind patient experience platform in rare diseases. Raremark helps patients and families to confront the realities of living with a rare condition by providing access to educational materials, clinical trials, innovative therapies and shared experiences through a personalized and self-paced experience.
The Raremark experience is powered by the Xperiome Platform, which utilises novel design and behavioural science techniques to create unique patient journeys, whilst providing biopharmaceutical companies with access to research ready populations to recruit to studies and generate anonymized and aggregated patient data unavailable elsewhere – supporting clinical development, accelerating speed to market and facilitating the evaluation of new treatments.
